UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer GlobeNewswire July 07, 2025 PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial […]

Mawer Announces Organizational Updates for the Global Equity Strategy

Mawer Announces Organizational Updates for the Global Equity Strategy GlobeNewswire July 07, 2025 CALGARY, Alberta, July 07, 2025 (GLOBE NEWSWIRE) — Mawer Investment Management Ltd. (“Mawer”) announced today that Paul Moroz, CFA, has assumed the role of lead portfolio manager and David Ragan, CFA, has assumed the role of co-manager for the Mawer Global Equity

Vortex Energy Announces ANT Survey Sampling Plan for Robinsons River Salt Project

Vortex Energy Announces ANT Survey Sampling Plan for Robinsons River Salt Project VORTEX ENERGY FINALIZES SAMPLING PLAN FOR ANT SURVEY AT ROBINSONS RIVER SALT PROJECT GlobeNewswire July 07, 2025 VANCOUVER, British Columbia, July 07, 2025 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company“) is pleased to announce

Suffolk County Transit Chooses NFI’s New Flyer to Modernize Fleet with 132 Next-Generation Buses

Suffolk County Transit Chooses NFI's New Flyer to Modernize Fleet with 132 Next-Generation Buses GlobeNewswire July 07, 2025 ST. CLOUD, Minn., July 07, 2025 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI) a leader in propulsion-agnostic bus and coach mobility solutions, subsidiary New Flyer of America Inc. (New Flyer), has

Limitless X Holdings, Inc. Enters $500 Billion Global Coffee and $2.5 Trillion CPG Market with Launch of Cognitive-Enhancing Nootropic Blend Coffee Concentrate

Limitless X Holdings, Inc. Enters $500 Billion Global Coffee and $2.5 Trillion CPG Market with Launch of Cognitive-Enhancing Nootropic Blend Coffee Concentrate GlobeNewswire July 07, 2025 Los Angeles, CA, July 07, 2025 (GLOBE NEWSWIRE) — Limitless X Holdings, Inc. (OTCQB: LIMX), a leading innovator in health, wellness, and performance-driven lifestyle solutions, proudly announces the official

Expert’s Presentation Exposes Massive Federal Resource That Could Quietly Fund Trump’s Ambitious New Agenda

Expert's Presentation Exposes Massive Federal Resource That Could Quietly Fund Trump's Ambitious New Agenda GlobeNewswire July 07, 2025 Baltimore, MD, July 07, 2025 (GLOBE NEWSWIRE) — A released presentation by economic strategist Jim Rickards is drawing fresh attention just as President Trump prepares to introduce his most sweeping economic legislation to date–a bill insiders are

Catheter Precision, Inc. Announces First Purchase Order From University Hospital in Rennes, France

Catheter Precision, Inc. Announces First Purchase Order From University Hospital in Rennes, France GlobeNewswire July 07, 2025 FORT MILL, S.C., July 07, 2025 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (VTAK – NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced today that it has received

LENZ Therapeutics and Laboratoires Thea Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

LENZ Therapeutics and Laboratoires Thea Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada Exclusive agreement includes over $70 million in upfront and milestone payments to LENZ in addition to double-digit royalties on net sales GlobeNewswire July 07, 2025 SAN DIEGO and CLERMONT-FERRAND, France, July 07, 2025 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq:

Chugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases

Chugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases GlobeNewswire July 07, 2025 Collaboration to create novel antibody drug candidates using Chugai's proprietary antibody engineering technologies for drug targets identified through Gero's AI-driven human data-first platform Accelerating the creation of innovation by combining Gero's aging-focused target discovery

Absci Appoints Biopharma Leader Mary Szela to Board of Directors

Absci Appoints Biopharma Leader Mary Szela to Board of Directors Former Abbott executive who led the US launch and global expansion of Humira(R) adds three decades of commercial and clinical leadership expertise GlobeNewswire July 07, 2025 VANCOUVER, Wash., July 07, 2025 (GLOBE NEWSWIRE) — Absci (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed

Scroll to Top